- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S7289
| Related Targets | CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase |
|---|---|
| Other PFKFB Inhibitors | 3PO PFK158 KAN0438757 |
|
In vitro |
DMSO
: 19 mg/mL
(72.99 mM)
Ethanol : 5 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 260.29 | Formula | C17 H12 N2 O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 4382-63-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | PFK-015 | Smiles | C1=CC=C2C(=C1)C=CC(=N2)C=CC(=O)C3=CC=NC=C3 | ||
| Targets/IC50/Ki |
PFKFB3
(Cell-free assay) 207 nM
|
|---|---|
| In vitro |
PFK15 produces potent growth inhibition in a series of cancer cells. In Jurkat T-cell leukemia cells and H522 lung adenocarcinoma cells, this compound also reduces F26BP, glucose uptake, and intracellular ATP level.
|
| Kinase Assay |
Recombinant PFKFB3 assay
|
|
Kinase reactions are conducted by incubating 13 ng of recombinant human PFKFB3 protein in a reaction mix containing 10 μmol/L ATP, 10 μmol/L F6P, and either dimethyl sulfoxide (DMSO) vehicle control, 3PO, or PFK15 for 1 hour at room temperature. Kinase activity is measured with the Adapta Universal Kinase Assay per manufacturer
|
|
| In vivo |
In vivo, PFK15 has adequate pharmacokinetic properties. This compound (25 mg/kg i.p.) suppresses the growth, metastatic spread, and glucose metabolism of LLC tumors in syngeneic mice. In three human xenograft models of cancer in athymic mice, it also yields antitumor effects that are comparable to approved chemotherapeutic agents.
|
References |
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | Cyclin E1 / CDK2 / Cyclin D1 / CDK4 / CDK6 / E2F1 / Rb / p-Rb |
|
27669567 |
| Growth inhibition assay | Cell viability |
|
27669567 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.